Prévisions
L'objectif de cours moyen des analystes est de 45,14 € (+50,02 %). La médiane est de 44,62 € (+48,29 %).
| Acheter |
8 |
| Conserver |
3 |
| Vendre |
2 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Harmony Biosciences outlines second growth chapter with BP-205 and acquisition plans
Harmony is building on revenue driver WAKIX (on track for over $1 billion) and a broader pipeline approach. The company has about $963 million in cash, positions BP-205 as a leading orexin‑2 agonist and plans two to three business-development transactions expected to generate revenue in 2028–2032. In parallel, Harmony is defending WAKIX’s patent portfolio against generics and anticipates loss of exclusivity in March 2030. Several clinical milestones for BP-205 are targeted for late 2024 to mid-2026. » Plus sur de.investing.com
Harmony Biosciences reaches 52-week high after strong Wakix numbers
Harmony Biosciences shares rose to a new 52-week high of $42.70 and have a market capitalization of about $2.49 billion. In the second quarter, adjusted earnings per share of $1.28 beat expectations, and Wakix revenue hit a record $261.3 million, confirming the full-year guidance of $1.00–1.04 billion. Analysts remain positive (including outperform ratings with price targets of $60–70), despite ongoing IP disputes and competition from orexin agonists. InvestingPro sees the stock at a fair value of $59.06 and rates the financial condition as "EXCELLENT". » Plus sur de.investing.com
Harmony Biosciences presents strategy following WAKIX and expands CNS pipeline
Harmony outlines three strategic pillars: expanding the pitolisant franchise with Pitolisant GR (PDUFA April 27) and Pitolisant HD; advancing BP-205 as a potential best-in-class orexin-2 agonist; and developing EPX-100 for rare epilepsies. WAKIX delivered record quarterly sales and funds the pipeline growth, while key milestones are mostly expected in 2027/2028. BP-205 showed strong efficacy, rapid absorption and no relevant safety signals in early studies; EPX-100 demonstrated substantial seizure reductions in Dravet syndrome. The stock closed at $38.50 (-3.19%). » Plus sur de.investing.com
Harmony Biosciences posts strong Q1 results, keeps full-year revenue guidance above $1 billion
Harmony Biosciences reported Q1 2026 revenue of $215.4 million, a 17% year-over-year increase driven by continued adoption of WAKIX (pitolisant). Management reaffirmed full-year 2026 net revenue guidance of over $1 billion and highlighted strong operating leverage and cash generation funding its late-stage pipeline. The company is pursuing pediatric narcolepsy approval and exploring indications including idiopathic hypersomnia and Prader-Willi syndrome, supporting investor optimism about lifecycle and pipeline growth. » Plus sur finance.yahoo.com
Harmony Biosciences: WAKIX grows, heavy investments weigh on quarterly profit
Harmony reported Q1 2026 results: WAKIX revenue rose 17% to $215.4 million but missed consensus, and diluted earnings per share fell to $0.55, well below expectations. Management reaffirmed the full-year revenue guidance of $1.0–1.04 billion, attributing the earnings miss to high strategic investments, license costs and increased R&D spending. The company holds about $870.5 million in cash and highlights growth drivers such as enteric-coated and high‑dose pitolisant programs, a broad pipeline and legal actions to defend patents. Despite near-term profitability pressure, Harmony sees a clear path for WAKIX to reach the billion-dollar mark and plans to step up business development transactions. » Plus sur de.investing.com
Données financières
Au dernier trimestre, HARMONY BIOSC.HLD.-,00001 a réalisé un chiffre d'affaires de 237,41 M € et un bénéfice net de 42,55 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 237,41 M | 16,35 % |
| Bénéfice brut | 166,18 M | 8,46 % |
| Bénéfice net | 42,55 M | 1,83 % |
| EBITDA | 60,28 M | 3,70 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,77 Md € |
Nombre d'actions | 58,72 M |
Plus haut/bas sur 52 semaines | 39,60 € - 23,58 € |
| Dividendes | Non |
Bêta | 0,98 |
Ratio P/E | 10,75 |
Ratio PEG | -2,18 |
Ratio P/B | 1,80 |
Ratio P/S | 1,97 |
Profil de l'entreprise
Harmony Biosciences Holdings, Inc., une entreprise pharmaceutique au stade de commercialisation, développe et commercialise des thérapies destinées aux patients atteints de troubles neurologiques rares aux États-Unis. Son produit, WAKIX, est un médicament destiné au traitement de la somnolence diurne excessive chez les patients adultes atteints de narcolepsie. La société était auparavant connue sous le nom de Harmony Biosciences II, Inc. et a changé sa dénomination en Harmony Biosciences Holdings, Inc. en février 2020. Harmony Biosciences Holdings, Inc. a été constituée en 2017 et a son siège à Plymouth Meeting, en Pennsylvanie.
| Nom | HARMONY BIOSC.HLD.-,00001 |
| PDG | Jeffrey Dayno |
| Siège social | Plymouth Meeting,
pa États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 19/08/2020 |
| Employés | 293 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | HRMY |